This title appears in the Scientific Report :
2012
Please use the identifier:
http://dx.doi.org/10.1016/j.nucmedbio.2012.04.003 in citations.
[(18)F]desmethoxyfallypride as a novel PET radiotracer for quantitative in vivo dopamine D2/D3 receptor imaging in rat models of neurodegenerative diseases
[(18)F]desmethoxyfallypride as a novel PET radiotracer for quantitative in vivo dopamine D2/D3 receptor imaging in rat models of neurodegenerative diseases
[(18)F]desmethoxyfallypride ([(18)F]DMFP) is a promising tracer for longitudinal assessment of striatal dopamine D2/D3-receptor (D2R) availability by positron emission tomography (PET) in small animal models. We explored the feasibility of [(18)F]DMFP-PET to image D2R availability in rat models of H...
Saved in:
Personal Name(s): | Döbrössy, M.D. |
---|---|
Braun, F. / Klein, S. / Garcia, J. / Langen, K.J. / Weber, W.A. / Nikkhah, G. / Meyer, P.T. | |
Contributing Institute: |
Physik der Medizinischen Bildgebung; INM-4 |
Published in: | Nuclear medicine and biology, 39 (2012) S. 1077 - 1080 |
Imprint: |
Amsterdam [u.a.]
Elsevier
2012
|
Physical Description: |
1077 - 1080 |
PubMed ID: |
22591915 |
DOI: |
10.1016/j.nucmedbio.2012.04.003 |
Document Type: |
Journal Article |
Research Program: |
Neuroimaging Funktion und Dysfunktion des Nervensystems |
Series Title: |
Nuclear Medicine and Biology
39 |
Subject (ZB): | |
Publikationsportal JuSER |
[(18)F]desmethoxyfallypride ([(18)F]DMFP) is a promising tracer for longitudinal assessment of striatal dopamine D2/D3-receptor (D2R) availability by positron emission tomography (PET) in small animal models. We explored the feasibility of [(18)F]DMFP-PET to image D2R availability in rat models of Huntington's (HD) and Parkinson's disease (PD).Animals received either unilateral intrastriatal quinolinic acid lesions or medial forebrain bundle injections of 6-OHDA to produce the loss of striatal projection neurones or deplete the striatal dopamine, corresponding to established animal models for HD and PD, respectively. Three weeks after lesioning, PET scans were acquired on a microPET Focus 120 system following the tail vein injection of [(18)F]DMFP.[(18)F]DMFP-PET clearly visualized lesion induced decreases and increases of D2R availability. In vivo estimates of D2R binding and changes thereof gained by pharmacokinetic analyses correlated significantly with D2R density and its change provided by in vitro [(3)H]raclopride-autoradiography.In conclusion, [(18)F]DMFP-PET is a suitable method for in vivo D2R-assessment in preclinical research, e.g for monitoring cell-based therapies. |